Phase Space AI

Trade Construction

Insmed [INSM]

Insmed [INSM] — Trade Construction

Spot $103.16 (2026-07-29). No position verdict is issued — the memo scores criteria; the book decides. What follows is the construction that would apply, and the vehicle argument.

Vehicle: EQUITY

Equity is the default and needs no argument. A LEAP was nevertheless tested against the standard — measured IV minus trailing 252-day realised vol — and fails:
Trailing 252-day realised volatility 54.1%
Measured IV, INSM 2027-08-20 $105 call 62.7%
Measured IV, INSM 2027-11-19 $105 call 61.7%
IV − realised +8.6pp — options are expensive

Constructability also fails at the strike. The 2027-08-20 $105 call quotes $25.33 bid / $28.65 ask, a 12.3% of mid spread, with quoted size 5 x 7 contracts. Open interest across the entire $95–$115 strike range for both 2027 expiries is 5 contracts on one line and reported as null on the other eleven. There is no size available at any reasonable price. Multi-leg is therefore also inadmissible: the requirement is constructability at the strike, with quoted size, and it does not exist.

Vehicle: common stock. No options.

Sizing constraint

Position size is constrained by the cash-runway and refinancing clock, not by liquidity. Average daily volume on the last two sessions was 126,627 and 140,685 shares, roughly $13–15m/day at $103 — thin for a $22.4bn market cap, which means an exit takes days, not hours. Size to what can be exited inside the two-day window around a Q2 print.

Entry and exit levels, all referenced to observable data

Level Basis
Spot $103.16 Alpaca close 2026-07-29
Post-approval price range $91.88 – $211.41 Daily closes since 2025-08-12, 242 sessions
Post-approval median $146.25 same
Drawdown from post-approval high −51.2% $211.41 → $103.12
12-month target $122.61, +18.9% Constant 9.40x EV/NTM sales, revenue window rolled to FY2027 consensus. See INSM_Valuation.md §5

The stock is 51.2% off its post-approval high and within 12.3% of its post-approval low. That is the setup: the market has already taken out the launch-euphoria premium. The implied-path test says it has not taken out enough.

Invalidation — what makes the thesis wrong, stated in advance

  1. BRINSUPRI Q2'26 below ~$240m (consensus implies roughly $280m). A launch decelerating in quarter four, against a 500,000-patient label, would confirm the frequent-exacerbator ceiling named in the downside case.
  2. Same-quarter DSO above 58 days in Q2'26 (from 52.5). Continued receivable extension against a decelerating top line is the AAOI signature.
  3. US ARIKAYCE down again year-on-year in Q2'26 (Q2'25 base: ARIKAYCE total $107.415m). Two consecutive quarters of US decline makes the attention-cannibalisation reading structural rather than transitional.
  4. Any new equity raise before 2027. Insmed has $1,223.5m and no ATM. A raise into a stock 51% off its high would mean the consensus burn trajectory is wrong.

What the trade is actually expressing

That the reimbursable bronchiectasis population is closer to the FDA's 500,000 than to the EC's and MHRA's frequent-exacerbator restriction. Everything else — the ARIKAYCE label expansion, TPIP's four Phase 3 programmes, the gene therapies — is second-order against that single question, and the valuation section shows the price already requires the optimistic answer plus a 78.3% terminal operating margin.